Table 2 Haematologic response by treatment group

From: Epoetin alfa in platinum-treated ovarian cancer patients: results of a multinational, multicentre, randomised trial

Haematologic response a

Epoetin alfa ( n= 112)

Best standard treatment ( n= 59)

Complete responders, n (%)

87 (77.7)

19 (32.2)

Partial responders, n (%)

4 (3.6)

6 (10.2)

Nonresponders, n (%)

21 (18.8)

34 (57.6)

  1. aComplete: Hb increase of ⩾1.0 g dl−1 above baseline without transfusion within previous 4 weeks; partial: Hb increase of ⩾0.5 g dl−1 but <1.0 g dl−1; no response: need for transfusion within previous 4 weeks or Hb increase of <0.5 g dl−1 above baseline. The difference in the proportions of both responders and nonresponders between the two treatment groups was statistically significant (P<0.001).
Back to article page